294 related articles for article (PubMed ID: 26778048)
1. Management of leptomeningeal metastases: Prognostic factors and associated outcomes.
Brower JV; Saha S; Rosenberg SA; Hullett CR; Ian Robins H
J Clin Neurosci; 2016 May; 27():130-7. PubMed ID: 26778048
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors and treatment options in patients with leptomeningeal metastases of different primary tumors: a retrospective analysis.
Oechsle K; Lange-Brock V; Kruell A; Bokemeyer C; de Wit M
J Cancer Res Clin Oncol; 2010 Nov; 136(11):1729-35. PubMed ID: 20204406
[TBL] [Abstract][Full Text] [Related]
3. Patient outcomes of whole brain radiotherapy for brain metastases versus leptomeningeal metastases: A retrospective study.
Sakaguchi M; Maebayashi T; Aizawa T; Ishibashi N; Saito T
Asia Pac J Clin Oncol; 2017 Oct; 13(5):e449-e457. PubMed ID: 27620060
[TBL] [Abstract][Full Text] [Related]
4. Concurrent radiotherapy and intrathecal methotrexate for treating leptomeningeal metastasis from solid tumors with adverse prognostic factors: A prospective and single-arm study.
Pan Z; Yang G; He H; Zhao G; Yuan T; Li Y; Shi W; Gao P; Dong L; Li Y
Int J Cancer; 2016 Oct; 139(8):1864-72. PubMed ID: 27243238
[TBL] [Abstract][Full Text] [Related]
5. Leptomeningeal metastasis: Clinical experience of 519 cases.
Hyun JW; Jeong IH; Joung A; Cho HJ; Kim SH; Kim HJ
Eur J Cancer; 2016 Mar; 56():107-114. PubMed ID: 26841095
[TBL] [Abstract][Full Text] [Related]
6. Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis.
Kuiper JL; Hendriks LE; van der Wekken AJ; de Langen AJ; Bahce I; Thunnissen E; Heideman DA; Berk Y; Buijs EJ; Speel EJ; Krouwels FH; Smit HJ; Groen HJ; Dingemans AM; Smit EF
Lung Cancer; 2015 Sep; 89(3):255-61. PubMed ID: 26117231
[TBL] [Abstract][Full Text] [Related]
7. The prognostic significance of surgically treated hydrocephalus in leptomeningeal metastases.
Jung TY; Chung WK; Oh IJ
Clin Neurol Neurosurg; 2014 Apr; 119():80-3. PubMed ID: 24635931
[TBL] [Abstract][Full Text] [Related]
8. Treatment of leptomeningeal carcinomatosis: current challenges and future opportunities.
Kak M; Nanda R; Ramsdale EE; Lukas RV
J Clin Neurosci; 2015 Apr; 22(4):632-7. PubMed ID: 25677875
[TBL] [Abstract][Full Text] [Related]
9. Outcome and prognostic factors in patients with brain metastases from small-cell lung cancer treated with whole brain radiotherapy.
Bernhardt D; Adeberg S; Bozorgmehr F; Opfermann N; Hoerner-Rieber J; König L; Kappes J; Thomas M; Herth F; Heußel CP; Warth A; Debus J; Steins M; Rieken S
J Neurooncol; 2017 Aug; 134(1):205-212. PubMed ID: 28560661
[TBL] [Abstract][Full Text] [Related]
10. Stereotactic radiosurgery to the resection bed for intracranial metastases and risk of leptomeningeal carcinomatosis.
Ojerholm E; Lee JY; Thawani JP; Miller D; O'Rourke DM; Dorsey JF; Geiger GA; Nagda S; Kolker JD; Lustig RA; Alonso-Basanta M
J Neurosurg; 2014 Dec; 121 Suppl():75-83. PubMed ID: 25434940
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcomes of breast leptomeningeal disease treated with intrathecal trastuzumab, intrathecal chemotherapy, or whole brain radiation therapy.
Figura NB; Rizk VT; Mohammadi H; Evernden B; Mokhtari S; Yu HM; Robinson TJ; Etame AB; Tran ND; Liu J; Washington I; Diaz R; Czerniecki BJ; Soliman H; Han HS; Sahebjam S; Forsyth PA; Ahmed KA
Breast Cancer Res Treat; 2019 Jun; 175(3):781-788. PubMed ID: 30859348
[TBL] [Abstract][Full Text] [Related]
12. [Clinical features and prognostic factors in patients with leptomeningeal metastases].
Li N; Yang BY; Li JL; Zhu JQ; Zou BH; Wang YF; Yu L; Yao XY
Zhonghua Zhong Liu Za Zhi; 2013 Nov; 35(11):867-70. PubMed ID: 24447488
[TBL] [Abstract][Full Text] [Related]
13. Management of leptomeningeal metastasis in breast cancer.
Assi HI; Mahmoud T; Saadeh FS; El Darsa H
Clin Neurol Neurosurg; 2018 Sep; 172():151-159. PubMed ID: 30015053
[TBL] [Abstract][Full Text] [Related]
14. Neoplastic meningitis-related prognostic significance of the Karnofsky performance status.
Chamberlain MC; Johnston SK; Glantz MJ
Arch Neurol; 2009 Jan; 66(1):74-8. PubMed ID: 19139302
[TBL] [Abstract][Full Text] [Related]
15. A molecular graded prognostic assessment (molGPA) model specific for estimating survival in lung cancer patients with leptomeningeal metastases.
Yin K; Li YS; Zheng MM; Jiang BY; Li WF; Yang JJ; Tu HY; Zhou Q; Zhong WZ; Yang XN; Chen HJ; Yan HH; Li LL; Wu YL; Zhang XC
Lung Cancer; 2019 May; 131():134-138. PubMed ID: 31027690
[TBL] [Abstract][Full Text] [Related]
16. Clinical features and outcome of leptomeningeal metastasis in patients with breast cancer: a single center experience.
Jo JC; Kang MJ; Kim JE; Ahn JH; Jung KH; Gong G; Kim HH; Ahn SD; Kim SS; Son BH; Ahn SH; Kim SB
Cancer Chemother Pharmacol; 2013 Jul; 72(1):201-7. PubMed ID: 23670641
[TBL] [Abstract][Full Text] [Related]
17. Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations.
Li YS; Jiang BY; Yang JJ; Tu HY; Zhou Q; Guo WB; Yan HH; Wu YL
J Thorac Oncol; 2016 Nov; 11(11):1962-1969. PubMed ID: 27539328
[TBL] [Abstract][Full Text] [Related]
18. Determinants of prolonged survival for breast cancer patient groups with leptomeningeal metastasis (LM).
Niwińska A; Pogoda K; Michalski W; Kunkiel M; Jagiełło-Gruszfeld A
J Neurooncol; 2018 May; 138(1):191-198. PubMed ID: 29435818
[TBL] [Abstract][Full Text] [Related]
19. Leptomeningeal metastases from breast cancer: intrinsic subtypes may affect unique clinical manifestations.
Lee S; Ahn HK; Park YH; Nam DH; Lee JI; Park W; Choi DH; Huh SJ; Park KT; Ahn JS; Im YH
Breast Cancer Res Treat; 2011 Oct; 129(3):809-17. PubMed ID: 21785952
[TBL] [Abstract][Full Text] [Related]
20. [Epidermal growth factor tyrosine kinase inhibitors used in the treatment of NSCLC patients with leptomeningeal metastasis].
Xu Y; Zhong W; Zhao J; Chen MJ; Zhang L; Li LY; Wang MZ
Zhonghua Zhong Liu Za Zhi; 2016 Dec; 38(12):920-924. PubMed ID: 27998469
[No Abstract] [Full Text] [Related]
[Next] [New Search]
